Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taligen Therapeutics Inc.

Division of Alexion Pharmaceuticals Inc.

Latest From Taligen Therapeutics Inc.

Business News, In Brief

Quintiles files IPO; Forest sees LAMA/LABA combo product, slated for a 2014 NDA, as filling out a suite of COPD drugs to cover the full range of disease severity. Plus news from a host of biopharma quarterly earnings calls.

BioPharmaceutical Strategy

GSK Will Be A Limited Partner In Sanderling Ventures’ New Fund

The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.

BioPharmaceutical Medical Device

With Trio Of 2011 Deals, Alexion Looks To Nearly Double R&D Spending In 2012

The biotech, which is enjoying growing sales of high-priced, ultra-orphan terminal complement inhibitor Soliris, also has a pipeline of four other clinical and preclinical candidates for rare diseases.

BioPharmaceutical Clinical Trials

Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition

Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alexion Pharmaceuticals Inc.
  • Senior Management
  • Sven Ante (Bill) Lundberg, MD, CMO
  • Contact Info
  • Taligen Therapeutics Inc.
    Phone: (617) 444-8443
    245 First St.
    Ste 1830
    Cambridge, MA 02142